归因人头的流失在合同续期时才被记录，但根源在于最初归因和早期就诊环节。 对医疗服务提供商而言，这一问题出现在特定位置。承载答案的数字是每例成本和支付方组合，而这一行业的特殊之处在于，已在38,000人头上接受下行风险，却缺乏定价所需每例成本数据。这个问题的通用版本与你实际面对的版本，第一步行动不同。
归因人头的流失在合同续期时才被记录，但根源在于最初归因和早期就诊环节。 对医疗服务提供商而言，这一问题出现在特定位置。承载答案的数字是每例成本和支付方组合，而这一行业的特殊之处在于，已在38,000人头上接受下行风险，却缺乏定价所需每例成本数据。这个问题的通用版本与你实际面对的版本，第一步行动不同。
基于价值合同下的大部分流失，在续期前早已决定——发生在初始归因、首次就诊，以及归因人头是否达到合同定价结果之时。支付方转移人头时给出的理由很少是真正原因；那只是最方便的说法。
有用的切分是按队列和早期就诊行为，而非退出理由。每例成本从一开始就得到控制的归因人头，其留存率和每提供商贡献永远不同，这些队列之间的差距通常大于支付方组合或后续支持的任何差异。
第二个有用的切分是面板规模和每提供商贡献，而非总归因人头。失去许多小面板与失去少数大面板，对合同下人头的影响相同，但对首席财务官或医疗总监的应对要求完全不同。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 基于价值合同下失去归因人头给出的理由前后不一，很少指向具体的每例成本问题。
✓ 留存率和每提供商贡献在不同面板间差异明显，与现有每例成本数据没有清晰关联。
✓ 必须持续新增归因人头，才能防止基于价值合同下的总人头下降。
通常会让情况更糟的做法。 在合同续期时才启动留存工作，这是干预成本最高、且在缺乏初始每例成本数据的情况下最难成功的时机。
It is for you if you run or finance a healthcare provider and cancellation reasons are vague and vary widely. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Sell coordinated care bundles directly to self-insured employers using existing clinic density and ASC capacity.
The leak it closes. Bypasses commercial payer take-rate (estimated 15–20% of premium) and prior-authorization friction, reducing denial leakage on these lives to near zero
The assumption it rests on. At least two of the five largest self-insured employers in the two metros will sign a 3-year direct contract within 18 months — the engine put the probability at 0.7.
| Investment required | $2M over 36 months ($800K Year 1, $700K Year 2, $500K Year 3) |
| Expected return | 6.0–9.0× on $2M investment |
| Revenue, year 1 | $0 incremental (pilot setup and first contract negotiations) |
| Revenue, year 2 | $4–6M incremental (2–3 employer contracts, 4,000–6,000 covered lives) |
| Revenue, year 3 | $12–18M incremental (5 employer contracts, 10,000–15,000 covered lives) |
| Exit criteria | Terminate pilot and redeploy 4 FTEs if fewer than 2 employer contracts signed by Month 18 OR if operating margin on employer channel falls below 6% for two consecutive quarters |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 价值创造蓝图, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
基准本身不如趋势和组合重要。对小账户合适的比率，对大账户可能是致命的；任何没有队列支撑的数字都只是装饰。
这会把流失问题转为利润率问题，通常只把损失推迟一个周期。只有在你已知原因并在该周期内修复时才值得做。
直接与获客对比：在现有基数上提高一个保留点，与买一个新增收入点所需的成本相比。对达到一定规模的大多数企业，保留成本低得多，因此值得在新一轮获客前先做分析。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית